Serum 20S Proteasome is Elevated in Patients with Renal Cell Carcinoma and Associated with Poor Prognosis

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Feb 2

PMID 22294183

Citations 15

Authors

M De Martino

K Hoetzenecker

H J Ankersmit

G A Roth

A Haitel

M Waldert

T Klatte

Affiliations

Soon will be listed here.

Abstract

Background: To date, no reliable serum marker for clear cell renal cell carcinoma (CCRCC) is available. The aim of this study was to evaluate the putative significance of circulating 20S proteasome levels.

Methods: Preoperative 20S proteasome serum levels were determined in 113 CCRCC patients and 15 healthy controls by a sandwich enzyme-linked immunosorbent assay. Associations with CCRCC, pathological variables, disease-specific survival (DSS), and response to sunitinib were evaluated.

Results: Median 20S proteasome levels were higher in CCRCC patients than in healthy controls (4.66 vs 1.52 μg ml(-1), P<0.0001). The area under the receiver operating characteristics curve curve was 87.1%. The 20S proteasome levels were associated with symptoms (P=0.0008), distant metastases (P=0.0011), grade (P=0.0247), and necrosis (P=0.0462). The 20S proteasome levels were identified as a prognostic factor for DSS in both univariable (hazards ratio 1.21, P<0.001) and multivariable (hazards ratio 1.17, P=0.0015) survival analysis. In patients responding to sunitinib, 20S proteasome levels were lower than in patients with stable disease and progressive disease.

Conclusion: This study demonstrates for the first time that increased 20S proteasome levels are associated with CCRCC, advanced disease, and poor prognosis. Routine use of this marker may allow better diagnosis, risk stratification, risk-adjusted follow-up, and identification of patients with a greater likelihood of response to targeted therapy.

Citing Articles

Metastasis from the tumor interior and necrotic core formation are regulated by breast cancer-derived angiopoietin-like 7.

Yamamoto A, Huang Y, Krajina B, McBirney M, Doak A, Qu S Proc Natl Acad Sci U S A. 2023; 120(10):e2214888120.

PMID: 36853945 PMC: 10013750. DOI: 10.1073/pnas.2214888120.

Identification and Verification of Potential Biomarkers in Renal Ischemia-Reperfusion Injury by Integrated Bioinformatic Analysis.

Pan Z, Yang Y, Cao R, Qiu Y, Li S, Zhao Y Biomed Res Int. 2023; 2023:7629782.

PMID: 36778059 PMC: 9911259. DOI: 10.1155/2023/7629782.

Functional and quantitative evaluation of the 20S proteasome in serum and intracellular in145 moroccan patients with hematologic malignancies.

Filali H, El Yaagoubi O, Ayoub Lahmadi , Quessar A, Antri S, Samaki H Clin Proteomics. 2022; 19(1):41.

PMID: 36380291 PMC: 9664591. DOI: 10.1186/s12014-022-09375-9.

The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?.

Cinque A, Capasso A, Vago R, Lee M, Floris M, Trevisani F Biomedicines. 2022; 10(1).

PMID: 35052770 PMC: 8773056. DOI: 10.3390/biomedicines10010090.

Concept and application of circulating proteasomes.

Choi W, Kim S, Park S, Lee M Exp Mol Med. 2021; 53(10):1539-1546.

PMID: 34707192 PMC: 8568939. DOI: 10.1038/s12276-021-00692-x.

References

Tisdale M . Pathogenesis of cancer cachexia. J Support Oncol. 2004; 1(3):159-68. View

Klatte T, Seligson D, Riggs S, Leppert J, Berkman M, Kleid M . Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007; 13(24):7388-93. DOI: 10.1158/1078-0432.CCR-07-0411. View

Corn P . Role of the ubiquitin proteasome system in renal cell carcinoma. BMC Biochem. 2007; 8 Suppl 1:S4. PMC: 2106368. DOI: 10.1186/1471-2091-8-S1-S4. View

Karakiewicz P, Briganti A, Chun F, Trinh Q, Perrotte P, Ficarra V . Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007; 25(11):1316-22. DOI: 10.1200/JCO.2006.06.1218. View

Klatte T, Bohm M, Nelius T, Filleur S, Reiher F, Allhoff E . Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU Int. 2007; 100(1):209-14. DOI: 10.1111/j.1464-410X.2007.06871.x. View

Szerafin T, Hoetzenecker K, Hacker S, Horvath A, Pollreisz A, Arpad P . Heat shock proteins 27, 60, 70, 90alpha, and 20S proteasome in on-pump versus off-pump coronary artery bypass graft patients. Ann Thorac Surg. 2007; 85(1):80-7. DOI: 10.1016/j.athoracsur.2007.06.049. View

Gore M, Larkin J . Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer. 2011; 104(3):399-406. PMC: 3049574. DOI: 10.1038/sj.bjc.6606084. View

Voges D, Zwickl P, Baumeister W . The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem. 2000; 68:1015-68. DOI: 10.1146/annurev.biochem.68.1.1015. View

Kanayama H, Tanaka K, AKI M, Kagawa S, Miyaji H, Satoh M . Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 1991; 51(24):6677-85. View

10.

Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J . The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol. 2010; 120(2):233-8. DOI: 10.1016/j.ygyno.2010.10.014. View

11.

Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L . Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer. 2011; 104(8):1256-61. PMC: 3078589. DOI: 10.1038/bjc.2011.103. View

12.

Ljungberg B, Hanbury D, Kuczyk M, Merseburger A, Mulders P, Patard J . Renal cell carcinoma guideline. Eur Urol. 2007; 51(6):1502-10. DOI: 10.1016/j.eururo.2007.03.035. View

13.

Groll M, Berkers C, Ploegh H, Ovaa H . Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006; 14(3):451-6. DOI: 10.1016/j.str.2005.11.019. View

14.

Stoebner P, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M . High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol. 2005; 152(5):948-53. DOI: 10.1111/j.1365-2133.2005.06487.x. View

15.

Jakob C, Egerer K, Liebisch P, Turkmen S, Zavrski I, Kuckelkorn U . Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood. 2006; 109(5):2100-5. DOI: 10.1182/blood-2006-04-016360. View

16.

Li G, Feng G, Gentil-Perret A, Genin C, Tostain J . Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol. 2008; 180(2):510-3. DOI: 10.1016/j.juro.2008.04.024. View

17.

Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak M, Allory Y . Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One. 2010; 5(5):e10715. PMC: 2873294. DOI: 10.1371/journal.pone.0010715. View

18.

Roth G, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S . Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest. 2005; 35(6):399-403. DOI: 10.1111/j.1365-2362.2005.01508.x. View

19.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

20.

Zisman A, Pantuck A, Wieder J, Chao D, Dorey F, Said J . Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20(23):4559-66. DOI: 10.1200/JCO.2002.05.111. View